Literature DB >> 16228913

Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics.

M Esler1, D Kaye.   

Abstract

Recent demonstration that the level of sympathetic nervous drive to the failing heart in patients with severe heart failure is a major determinant of prognosis, and that mortality in heart failure is reduced by beta-adrenergic blockade, indicate the clinical relevance of heart failure neuroscience research. The cardiac sympathetic nerves are preferentially stimulated in severe heart failure, with the application of isotope dilution methods for measuring cardiac norepinephrine release to plasma indicating that in untreated patients cardiac norepinephrine spillover is increased as much as 50-fold, similar to levels of release seen in the healthy heart during near maximal exercise. This preferential activation of the cardiac sympathetic outflow contributes to arrhythmia development and to progressive deterioration of the myocardium, and has been linked to mortality in both mild and severe cardiac failure. Although the central nervous system mechanisms involved in the sympathetic nervous activation at present remain uncertain, increased intracardiac diastolic pressure seems to be one peripheral reflex stimulus, and increased forebrain norepinephrine turnover an important central mechanism.Additional neurophysiological abnormalities present in the failing human heart include release of the sympathetic cotransmitters, epinephrine and neuropeptide Y, at high levels more typical of their release during exercise in healthy subjects, and the possible presynaptic augmentation of norepinephrine release from the cardiac sympathetic nerves by the regionally released epinephrine. Following on the demonstrable benefit of beta-adrenergic blockade in heart failure, additional antiadrenergic measures (central suppression of sympathetic outflow with imidazoline binding agents such as clonidine, blocking of norepinephrine synthesis by dopamine-beta-hydroxylase inhibition, antagonism of neuropeptide Y) are now under active investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 16228913     DOI: 10.1023/A:1009889922985

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  45 in total

1.  Cardiac sympathetic nerve function in congestive heart failure.

Authors:  G Eisenhofer; P Friberg; B Rundqvist; A A Quyyumi; G Lambert; D M Kaye; I J Kopin; D S Goldstein; M D Esler
Journal:  Circulation       Date:  1996-05-01       Impact factor: 29.690

2.  Combined sympathetic suppression and angiotensin-converting enzyme inhibition in congestive heart failure.

Authors:  A J Manolis; C Olympios; M Sifaki; S Handanis; D Cokkinos; M Bresnahan; I Gavras; H Gavras
Journal:  Hypertension       Date:  1997-01       Impact factor: 10.190

3.  Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans.

Authors:  M J Morris; H S Cox; G W Lambert; D M Kaye; G L Jennings; I T Meredith; M D Esler
Journal:  Hypertension       Date:  1997-01       Impact factor: 10.190

Review 4.  Neurohumoral activation in heart failure: role of paraventricular nucleus.

Authors:  K P Patel; K Zhang
Journal:  Clin Exp Pharmacol Physiol       Date:  1996-08       Impact factor: 2.557

5.  Increased central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients.

Authors:  G W Lambert; D M Kaye; J Lefkovits; G L Jennings; A G Turner; H S Cox; M D Esler
Journal:  Circulation       Date:  1995-10-01       Impact factor: 29.690

6.  Adverse consequences of high sympathetic nervous activity in the failing human heart.

Authors:  D M Kaye; J Lefkovits; G L Jennings; P Bergin; A Broughton; M D Esler
Journal:  J Am Coll Cardiol       Date:  1995-11-01       Impact factor: 24.094

7.  Exercise training lowers resting renal but not cardiac sympathetic activity in humans.

Authors:  I T Meredith; P Friberg; G L Jennings; E M Dewar; V A Fazio; G W Lambert; M D Esler
Journal:  Hypertension       Date:  1991-11       Impact factor: 10.190

8.  Adrenergic effects on the biology of the adult mammalian cardiocyte.

Authors:  D L Mann; R L Kent; B Parsons; G Cooper
Journal:  Circulation       Date:  1992-02       Impact factor: 29.690

9.  Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias.

Authors:  I T Meredith; A Broughton; G L Jennings; M D Esler
Journal:  N Engl J Med       Date:  1991-08-29       Impact factor: 91.245

10.  Neuronal uptake, metabolism, and release of tritium-labeled norepinephrine during assessment of its plasma kinetics.

Authors:  G Eisenhofer; M D Esler; D S Goldstein; I J Kopin
Journal:  Am J Physiol       Date:  1991-10
View more
  27 in total

Review 1.  What will be the role of I-123 MIBG in improving the outcome of medically treated heart failure patients?

Authors:  Fahad Waqar; Stephanie H Dunlap; Myron C Gerson
Journal:  J Nucl Cardiol       Date:  2012-12       Impact factor: 5.952

Review 2.  Targeting cardiac mast cells: pharmacological modulation of the local renin-angiotensin system.

Authors:  Alicia C Reid; Jacqueline A Brazin; Christopher Morrey; Randi B Silver; Roberto Levi
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

3.  Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2010

4.  TNF receptor signaling inhibits cardiomyogenic differentiation of cardiac stem cells and promotes a neuroadrenergic-like fate.

Authors:  Tariq Hamid; Yuanyuan Xu; Mohamed Ameen Ismahil; Qianhong Li; Steven P Jones; Aruni Bhatnagar; Roberto Bolli; Sumanth D Prabhu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-02       Impact factor: 4.733

5.  Determination of endogenous norepinephrine levels in different chambers of the rat heart by capillary electrophoresis coupled with amperometric detection.

Authors:  Martin Novotny; Veronika Quaiserová-Mocko; Erica A Wehrwein; David L Kreulen; Greg M Swain
Journal:  J Neurosci Methods       Date:  2007-02-16       Impact factor: 2.390

6.  Symbolic analysis detects alterations of cardiac autonomic modulation in congestive heart failure rats.

Authors:  Eleonora Tobaldini; Alberto Porta; Shun-Guang Wei; Zhi-Hua Zhang; Joseph Francis; Karina Rabello Casali; Robert M Weiss; Robert B Felder; Nicola Montano
Journal:  Auton Neurosci       Date:  2009-04-28       Impact factor: 3.145

7.  Cardiac hypertrophy in neonatal nephrectomized rats: the role of the sympathetic nervous system.

Authors:  Siddhartha S Ghosh; Richard J Krieg; Domenic A Sica; Ruipeng Wang; Itaf Fakhry; Todd Gehr
Journal:  Pediatr Nephrol       Date:  2008-09-17       Impact factor: 3.714

8.  Phospholipase Cbeta4 isozyme is expressed in human, rat, and murine heart left ventricles and in HL-1 cardiomyocytes.

Authors:  David Otaegui; Ramón Querejeta; Ander Arrieta; Ane Lazkano; Angel Bidaurrazaga; Jose Ramón Arriandiaga; Pablo Aldazabal; Mikel Asier Garro
Journal:  Mol Cell Biochem       Date:  2009-10-24       Impact factor: 3.396

9.  Natriuretic peptide-induced catecholamine release from cardiac sympathetic neurons: inhibition by histamine H3 and H4 receptor activation.

Authors:  Noel Yan-Ki Chan; Pablo A Robador; Roberto Levi
Journal:  J Pharmacol Exp Ther       Date:  2012-08-24       Impact factor: 4.030

10.  Effect of stellate ganglionectomy on basal cardiovascular function and responses to beta1-adrenoceptor blockade in the rat.

Authors:  Misa Yoshimoto; Erica A Wehrwein; Martin Novotny; Greg M Swain; David L Kreulen; John W Osborn
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-17       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.